News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

A team at Montana State University published research this week that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The work reveals a new process in human cells that has potential for treating a wide variety of genetic diseases.  Postdoctoral researchers Artem Nemudryi and Anna Nemudraia conducted the research alongside Blake Wiedenheft, professor in the Department of Microbiology and Cell Biology in MSU’s College of Agriculture. The paper, titled “Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in […]

University of Montana Center for Translational Medicine and Inimmune
|
April 22, 2024

A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.

University of Montana
|
April 14, 2024

University of Montana researchers and their partners have found a new method to generate human cartilage of the head and neck.

Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.

A message from Scott Whittenburg, UM Vice President for Research and Creative Scholarship: “I’m happy to report that the research enterprise at UM continues to grow.”

ARTICLES OF INTEREST

The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.

Bio.News
|
May 22, 2023

Drug makers have been racing at a breakneck pace to develop respiratory syncytial virus (RSV) vaccines this year. On May 3, the U.S. Food and Drug Administration (FDA) announced it has approved Arexvy, the first-ever RSV vaccine for individuals 60 and over.

National Institutes of Health
|
May 5, 2023

Information on Small Business Funding Webinar, National Small Business Week, America’s SEED Fund Week — and more

National Institutes of Health
|
March 27, 2023

SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year. The next deadline is April 5. Omnibus Solicitations. Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These FOAs do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations. Specific Funding […]

FDA advisers endorsed the safety and efficacy of GSK’s respiratory syncytial virus (RSV) vaccine in older adults, setting up a final mad dash with Pfizer as both companies eye the regulatory finish line with their promising new vaccines.

NEWSLETTER

Newsletter
|
April 19, 2024

View the Spring 2024 Newsletter now!

Newsletter
|
February 20, 2024

View the Winter II 2024 Newsletter now!